Could a shot every 6 months end HIV? new study tests lenacapavir in south africa

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants must be HIV negative at baseline \- 15-35 years * All participants must have a body weight ¬\> 35kg at baseline * All participants must be currently resident in the study area * All participants must be able to provide written, informed voluntary consent to partake in the study and willing and able to receive an injectable PrEP product * All participants must be sexually active (has had ≥ 2 intercourse encounters within the last 3 months) Exclusion Criteria: * Confirmed HIV-positive test result and/or signs and symptoms of an acute HIV infection * Unknown or indeterminate HIV-1 status at screening or enrolment. * Suspected or known serious infection(s), such as active tuberculosis * Severe hepatic impairment or renal disease * Allergy or hypersensitivity to any of the PrEP agents * Known chronic Hepatitis B infection and currently taking oral PrEP * Use of contraindicated medications for LEN: ergot derivatives (ergotamine, ergonovine, dihydroergotamine, methylergonovine, ergometrine), and certain anticonvulsants. * Concomitant Use of known enzyme-inducing or contraindicated medications including: rifampicin, rifapentine, phenytoin, phenobarbital, carbamazepine and oxcarbazepine. * Do not spend a reasonable amount of time in the study area as residents, for school, or work, or are otherwise unable to participate in study visits for geographical reasons, according to the site investigator * Medical, social or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records) * Current enrolment in another interventional research study that in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (as verified by registration on the South African Medical Research Council (SAMRC) biometric co-enrolment prevention system (BCEPS)).